Business
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
GAITHERSBURG, Md., January 12, 2026--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.
About this update from Genedx Holdings Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":417,"url":"https://media.zenfs.com/en/business-wire.com/3d7d10f568b1073f1dc5e52403f32d12"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SYUaaGmCbtc6nWs9nD7ZPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3d7d10f568b1073f1dc5e52403f32d12","width":960,"height":334},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YshwPkE59nFA0f7W4YsXLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MzQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3d7d10f568b1073f1dc5e52403f32d12","width":1200,"height":417}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit)","length":125,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expects fourth quarter 2025 revenues of $121 million, with exome and genome revenue up 32% (43% excluding a one-time 2024 benefit)","length":130,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expects full year 2025 exome and genome volume growth of more than 30%, with the fourth quarter 2025 accelerating to 34.3%","length":122,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expects full year 2025 and fourth quarter 2025 adjusted gross margin of 71%","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Issues full year 2026 guidance expecting revenues between $540 and $555 million, with 33-35% exome and genome growth","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":568,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., January 12, 2026--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025.","length":255,"tagName":"p"},{"type":"text","content":""In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment families need answers. In doing so, we delivered on our commitment to high growth and profitability, thanks to the...